## Shahla Bari

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6443869/publications.pdf

Version: 2024-02-01

1937685 2053705 5 7 51 4 citations h-index g-index papers 9 9 9 60 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Antiâ€N and antiâ€Do <sup>a</sup> immunoglobulin G alloantibody–mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOCâ€201: case report and review of the literature. Transfusion, 2019, 59, 1907-1910.	1.6	20
2	Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. Journal of Oncology, 2019, 2019, 1-5.	1.3	17
3	Awareness, Use and Outlook of Complementary and Alternative Medicine (CAM) Options in an Underserved, Uninsured Minority Cancer Patient Population. Integrative Cancer Therapies, 2021, 20, 153473542110516.	2.0	8
4	Comparison of Pre- and Post-translational Expressions of COXIV-1 and MT-ATPase 6 Genes in Colorectal Adenoma-Carcinoma Tissues [NIH-NIGMS]. Journal of Carcinogenesis & Mutagenesis, 2018, 09, .	0.3	4
5	2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. Open Forum Infectious Diseases, 2018, 5, S663-S663.	0.9	O
6	Prognostic significance of microsatellite instability (MSI) and mismatch repair status (MMR) in African American (AA) patients with colorectal cancer (CRC) and its impact on therapy with 5Fluorouracil Journal of Clinical Oncology, 2018, 36, e15634-e15634.	1.6	0
7	Efficacy and safety profile of PD-1 and pdl-1 inhibitors in African American patients Journal of Clinical Oncology, 2018, 36, e15080-e15080.	1.6	0